ALK202 for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called ALK202, a potential drug for people with advanced solid tumors. The main goal is to determine if ALK202 is safe and to establish the right dose for future studies. Participants should have cancer that has spread and can be measured by doctors, and they should feel well enough to perform daily activities.
As a Phase 1 trial, participants will be among the first to receive this treatment, aiding researchers in understanding how it works in people.
Do I have to stop taking my current medications for the ALK202 trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that ALK202 is likely to be safe for humans?
Research is examining the safety and tolerability of ALK202 in individuals with advanced solid tumors. This marks the first human trial of ALK202, so no prior safety data from human studies exists. As a Phase 1 trial, the primary goal is to assess safety and determine the optimal dose for future studies. Phase 1 trials focus on safety, with close monitoring of any side effects. Although specific safety data is not yet available, the study is designed to carefully observe participants' responses to the treatment.12345
Why do researchers think this study treatment might be promising?
Researchers are excited about ALK202 because it offers a novel approach to cancer treatment by targeting specific genetic mutations involved in tumor growth. Unlike traditional chemotherapy, which attacks rapidly dividing cells indiscriminately, ALK202 is designed to specifically inhibit the anaplastic lymphoma kinase (ALK) pathway, potentially leading to more precise and effective treatment with fewer side effects. This targeted mechanism could mean better outcomes for patients whose cancers are driven by these genetic alterations, making ALK202 a promising new option in the fight against cancer.
What evidence suggests that ALK202 might be an effective treatment for advanced solid tumors?
Research has shown that ALK202 might be a promising treatment for advanced solid tumors. Early results suggest that ALK202, which targets proteins that aid tumor growth, could help shrink tumors. This trial studies ALK202 to assess its safety and effectiveness in halting cancer progression. Although human studies provide limited information, the mechanism of ALK202 offers hope for slowing or stopping tumor growth. Early research focuses on understanding how the body processes the drug and its overall impact on tumors.12678
Are You a Good Fit for This Trial?
This trial is for adults aged 18-75 with advanced solid tumors, measurable by standard criteria, who have a life expectancy of at least 3 months and are in relatively good physical condition. They must have functioning organs and agree to use effective contraception. Those who can't join include women who may be pregnant or breastfeeding.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose-escalation
Participants receive escalating doses of ALK202 to determine the maximum tolerated dose (MTD)
Dose-expansion
Participants receive the recommended dose of ALK202 to further evaluate safety and antitumor activity
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- ALK202
Find a Clinic Near You
Who Is Running the Clinical Trial?
Shanghai Allink Biotherapeutics Co., Ltd.
Lead Sponsor